Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Sequential Docetaxel Followed by Epirubicin-Vinorelbine as First-line Chemotherapy in Advanced Breast Cancer

PATRIZIA VICI, PAOLO FOGGI, GIUSEPPE COLUCCI, ELISABETTA CAPOMOLLA, MARIO BRANDI, FRANCESCO GIOTTA, NICOLA GEBBIA, LUIGI DI LAURO, MARIA ROSARIA VALERIO, GIANCARLO PAOLETTI, FRANCA BELLI, CARMINE PIZZA, DIANA GIANNARELLI and MASSIMO LOPEZ
Anticancer Research March 2005, 25 (2B) 1309-1314;
PATRIZIA VICI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PAOLO FOGGI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIUSEPPE COLUCCI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELISABETTA CAPOMOLLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIO BRANDI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCESCO GIOTTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLA GEBBIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUIGI DI LAURO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA ROSARIA VALERIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIANCARLO PAOLETTI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCA BELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CARMINE PIZZA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIANA GIANNARELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASSIMO LOPEZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lopez@ifo.it
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 25 no. 2B 1309-1314
PubMed 
15865083

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received October 2, 2004
  • Accepted December 28, 2004
  • Published online March 1, 2005.

Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. PATRIZIA VICI1,
  2. PAOLO FOGGI1,
  3. GIUSEPPE COLUCCI2,
  4. ELISABETTA CAPOMOLLA1,
  5. MARIO BRANDI2,
  6. FRANCESCO GIOTTA2,
  7. NICOLA GEBBIA3,
  8. LUIGI DI LAURO1,
  9. MARIA ROSARIA VALERIO3,
  10. GIANCARLO PAOLETTI1,
  11. FRANCA BELLI1,
  12. CARMINE PIZZA4,
  13. DIANA GIANNARELLI1 and
  14. MASSIMO LOPEZ1
  1. 1Regina Elena Institute for Cancer Research, Via Elio Chianesi 53, 00144 Rome
  2. 2Oncologic Scientific Institute, Via Amendola 209, 70126 Bari
  3. 3Clinical Oncology, Policlinic University, Via del Vespro 129, 90127 Palermo
  4. 4S. Maria della PietĂ  Hospital, Nola (Naples), Via Seminario, 80035 Italy
  1. Correspondence to: Massimo Lopez, MD, Division of Medical Oncology B, Regina Elena Institute for Cancer Research, Via E. Chianesi, 53, 00144 - Rome, Italy. Tel: +3906 52666646, Fax: +3906 52665075, e-mail: lopez{at}ifo.it

Cited By...

  • 3 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (2B)
Anticancer Research
Vol. 25, Issue 2B
1 Mar 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sequential Docetaxel Followed by Epirubicin-Vinorelbine as First-line Chemotherapy in Advanced Breast Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Sequential Docetaxel Followed by Epirubicin-Vinorelbine as First-line Chemotherapy in Advanced Breast Cancer
PATRIZIA VICI, PAOLO FOGGI, GIUSEPPE COLUCCI, ELISABETTA CAPOMOLLA, MARIO BRANDI, FRANCESCO GIOTTA, NICOLA GEBBIA, LUIGI DI LAURO, MARIA ROSARIA VALERIO, GIANCARLO PAOLETTI, FRANCA BELLI, CARMINE PIZZA, DIANA GIANNARELLI, MASSIMO LOPEZ
Anticancer Research Mar 2005, 25 (2B) 1309-1314;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Sequential Docetaxel Followed by Epirubicin-Vinorelbine as First-line Chemotherapy in Advanced Breast Cancer
PATRIZIA VICI, PAOLO FOGGI, GIUSEPPE COLUCCI, ELISABETTA CAPOMOLLA, MARIO BRANDI, FRANCESCO GIOTTA, NICOLA GEBBIA, LUIGI DI LAURO, MARIA ROSARIA VALERIO, GIANCARLO PAOLETTI, FRANCA BELLI, CARMINE PIZZA, DIANA GIANNARELLI, MASSIMO LOPEZ
Anticancer Research Mar 2005, 25 (2B) 1309-1314;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire